M
Montserrat Camps
Researcher at Merck Serono
Publications - 73
Citations - 8670
Montserrat Camps is an academic researcher from Merck Serono. The author has contributed to research in topics: Mitogen-activated protein kinase & MAP2K7. The author has an hindex of 37, co-authored 73 publications receiving 8263 citations. Previous affiliations of Montserrat Camps include University of Barcelona & Merck KGaA.
Papers
More filters
Journal ArticleDOI
Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells.
Mercè de Frias,Daniel Iglesias-Serret,Ana M. Cosialls,Diana M. González-Gironès,Alba Pérez-Perarnau,Camila Rubio-Patiño,Thomas Rückle,Montserrat Camps,Alberto Fernández de Sevilla,Esmeralda de la Banda,Gabriel Pons,Joan Gil +11 more
TL;DR: The effect of isoform-selective PI3K inhibitors in the viability of CLL cells and lymphocytes from healthy donors is examined.
ASK1 promotes the contact hypersensitivity response through IL-17
Takehiro Sato,Montserrat Camps,Hong Ji,Thomas Rueckle,Dominique Swinnen,Ryoji Tsuboi,Kohsuke Takeda,Hidenori Ichijo +7 more
TL;DR: In this article, the authors show that ASK1 activation during the elicitation phase is sufficient to attenuate contact hypersensitivity (CHS) and that suppression of ASK 1 activity during the elicit phase through a chemical genetic approach or a specific inhibitory compound significantly reduced the CHS response to a level similar to that observed in ASk1 KO mice.
Patent
Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
Halazy Serge,Dennis Church,Montserrat Camps,Gotteland Jean-Pierre,Rueckle Thomas,Biamonte Marco,Arkinstall Stephen +6 more
TL;DR: In this article, the present invention is related to benzsulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such derivatives.
Patent
Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases
Arkinstall Stephen,Biamonte Marco,Montserrat Camps,Dennis Church,Jean Pierre Gotteland,Halazy Serge,Rueckle Thomas +6 more
Abstract: The present invention is related to substantially hydrophilic sulfonamide derivatives, or sulfonamide derivatives having a substantially hydrophilic moiety, of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formula-tions containing such sulfonamide derivatives. Said sulfonamide derivatives are effi-cient modulators of the JNK pathway, they are in particular efficient and selective in-hibitors of JNK 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula (I) according to the present invention being suitable pharma-ceutical agents are those wherein Ar1 is a substituted or unsubstituted aryl or heteroaryl; Ar2 is an aryl or heteroaryl group carrying at least one hydrophilic substituent;X is O or S, preferably O; R1 is hydrogen or a C?1?-C6-alkyl group, or R?1? forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula (I) is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula (I) thus providing a sulfonamide.
Patent
Scintillation proximity assays for aminoglycoside binding molecules
Montserrat Camps,Chabert Christian,Thierry Martin,Dominique Perrin,Christian Rommel,Matthias P. Wymann +5 more
TL;DR: In this paper, the scintillation proximity effect is exploited to identify and quantify Aminoglycoside Binding Molecules (ABMs), enzymes modifying such molecules, and compounds modulating the interaction between ABMs and either enzymes or aminoglycosides.